Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATXI Stock Price Chart Interactive Chart >
ATXI Price/Volume Stats
|Current price||$1.48||52-week high||$20.40|
|Prev. close||$1.42||52-week low||$1.24|
|Day high||$1.53||Avg. volume||1,325,167|
|50-day MA||$3.33||Dividend yield||N/A|
|200-day MA||$4.87||Market Cap||7.07M|
Avenue Therapeutics, Inc. (ATXI) Company Bio
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.
Most Popular Stories View All
ATXI Latest News Stream
|Loading, please wait...|
ATXI Latest Social Stream
View Full ATXI Social Stream
Latest ATXI News From Around the Web
Below are the latest news stories about AVENUE THERAPEUTICS INC that investors may wish to consider to help them evaluate ATXI as an investment opportunity.
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial results and recent corporate highlights for the third quarter ended September 30, 2022. “I am pleased that Avenue has achieved important financial milestones providing a path to continue developing drug
Avenue Therapeutics Inc (NASDAQ: ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ: FBIO). Founded in December 2019, Baergic Bio focuses on developing a pharmaceutical product for CNS disorders. Its pipeline currently includes a single compound, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator, which was in-licensed from AstraZeneca Plc (NASDAQ: AZN).
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“CNS”) diseases, today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc. Founded in December 2019, Bae
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI).
ATXI Price Returns